Ernexa Therapeutics Inc. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ernexa Therapeutics Inc. stock issued during period, value, other for the quarter ending 2026-06-30 was $0.00.
- Ernexa Therapeutics Inc. stock issued during period, value, other for the quarter ending 2026-03-31 was $18.00K, a 350.00% increase year-over-year.
- Ernexa Therapeutics Inc. stock issued during period, value, other for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. stock issued during period, value, other for the quarter ending 2025-09-30 was $26.00K.
- Ernexa Therapeutics Inc. stock issued during period, value, other for fiscal 2025 was $30.00K, a 97.01% decline from fiscal 2024.
- Ernexa Therapeutics Inc. stock issued during period, value, other for fiscal 2024 was $1.00M.
- Ernexa Therapeutics Inc. stock issued during period, value, other for fiscal 2020 was -$28.00K.
- Ernexa Therapeutics Inc. stock issued during period, value, other for fiscal 2018 was $1.38M.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $44.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.00K 10-Q · filed 2026-05-11 | $44.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $30.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $26.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $1.00M 10-K · filed 2025-03-12 | |
| 2020-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$28.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | -$9.00K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$6.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$3.00K 10-Q · filed 2020-05-20 | |
| 2019-03-31 | -$5.00K 10-Q · filed 2020-05-20 | $1.37M derived: sum of 4 quarters · filed 2020-05-20 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $1.38M 10-K · filed 2020-03-19 |
| 2018-09-30 | -$6.00K 10-Q · filed 2019-11-01 | |
| 2018-06-30 | $1.38M 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |